|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||301.302 g/mol g·mol−1|
|3D model (JSmol)|
A 2019 review found tentative evidence of benefit in anxiety.
Development of ocinaplon is discontinued due to liver complications that occurred in one of the Phase III subjects.
Condensation of 4-Acetylpyridine with N,N-Dimethylformamide dimethyl acetal (DMFDMA) gives the "enamide" (3). This is then condensed with (3-Amino-1H-pyrazol-4-yl)(2-pyridinyl)methanone (4) (96219-90-8). This is the same intermediate as was used in the synthesis of zaleplon in which the nitrile is replaced by a 2-acetylpyridil moiety. This affords the anxiolytic agent ocinaplon (5).